Equities Analysts Offer Predictions for VRDN FY2025 Earnings

Viridian Therapeutics, Inc. (NASDAQ:VRDN) – Analysts at Wedbush decreased their FY2025 earnings estimates for shares of Viridian Therapeutics in a research note issued on Wednesday, November 5th. Wedbush analyst L. Chico now forecasts that the company will post earnings per share of ($3.12) for the year, down from their prior forecast of ($2.84). The consensus estimate for Viridian Therapeutics’ current full-year earnings is ($4.03) per share. Wedbush also issued estimates for Viridian Therapeutics’ Q4 2025 earnings at ($0.91) EPS, Q1 2026 earnings at ($0.95) EPS, Q2 2026 earnings at ($0.95) EPS, Q3 2026 earnings at ($1.03) EPS, Q4 2026 earnings at ($0.91) EPS, FY2026 earnings at ($3.84) EPS, FY2027 earnings at ($2.59) EPS and FY2028 earnings at $3.30 EPS.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.48. Viridian Therapeutics had a negative net margin of 112,806.88% and a negative return on equity of 78.95%. The firm had revenue of $0.07 million for the quarter, compared to the consensus estimate of $16.21 million. The business’s quarterly revenue was up 81993.0% on a year-over-year basis.

Several other equities analysts also recently weighed in on VRDN. Royal Bank Of Canada raised their price objective on Viridian Therapeutics from $41.00 to $45.00 and gave the company an “outperform” rating in a research note on Thursday. The Goldman Sachs Group reissued a “buy” rating and issued a $40.00 target price on shares of Viridian Therapeutics in a report on Thursday. Needham & Company LLC cut their price target on Viridian Therapeutics from $36.00 to $34.00 and set a “buy” rating for the company in a research note on Wednesday, August 6th. Jefferies Financial Group initiated coverage on shares of Viridian Therapeutics in a research note on Monday, August 25th. They issued a “buy” rating and a $44.00 price objective on the stock. Finally, BTIG Research restated a “buy” rating and set a $61.00 target price on shares of Viridian Therapeutics in a research report on Tuesday. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Viridian Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $39.78.

Viridian Therapeutics Price Performance

VRDN stock opened at $27.50 on Friday. The firm has a 50 day moving average of $21.12 and a 200-day moving average of $17.41. The company has a market cap of $2.25 billion, a price-to-earnings ratio of -7.18 and a beta of 0.72. The company has a current ratio of 11.01, a quick ratio of 11.01 and a debt-to-equity ratio of 0.04. Viridian Therapeutics has a 12-month low of $9.90 and a 12-month high of $28.60.

Institutional Trading of Viridian Therapeutics

A number of hedge funds have recently bought and sold shares of VRDN. Amalgamated Bank raised its holdings in Viridian Therapeutics by 49.7% in the 1st quarter. Amalgamated Bank now owns 2,531 shares of the company’s stock valued at $34,000 after acquiring an additional 840 shares during the last quarter. Principal Financial Group Inc. grew its position in shares of Viridian Therapeutics by 17.0% in the first quarter. Principal Financial Group Inc. now owns 208,836 shares of the company’s stock valued at $2,815,000 after purchasing an additional 30,392 shares during the period. Bank of New York Mellon Corp increased its stake in Viridian Therapeutics by 0.8% in the first quarter. Bank of New York Mellon Corp now owns 198,177 shares of the company’s stock valued at $2,671,000 after purchasing an additional 1,655 shares during the last quarter. Rice Hall James & Associates LLC lifted its position in Viridian Therapeutics by 579.9% during the first quarter. Rice Hall James & Associates LLC now owns 362,893 shares of the company’s stock worth $4,892,000 after buying an additional 309,518 shares during the period. Finally, Victory Capital Management Inc. boosted its stake in Viridian Therapeutics by 34.7% in the 1st quarter. Victory Capital Management Inc. now owns 552,850 shares of the company’s stock worth $7,452,000 after buying an additional 142,410 shares during the last quarter.

Insider Buying and Selling

In related news, Director Fairmount Funds Management Llc acquired 454,545 shares of the company’s stock in a transaction that occurred on Thursday, October 23rd. The stock was purchased at an average price of $22.00 per share, for a total transaction of $9,999,990.00. Following the transaction, the director owned 3,914,458 shares in the company, valued at $86,118,076. This trade represents a 13.14% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 1.58% of the company’s stock.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.